Exploiting dual-energy CT and DirectSPR software to reduce range uncertainty in proton therapy

Due diligence: the stepwise validation of DirectSPR in different scenarios, such as in an anthropomorphic head phantom, was a fundamental step in the successful translation of the software into the clinical workflow. Even in the formative stages of DirectSPR algorithm development, OncoRay’s Christian Richter (right), shown here with fellow researcher Patrick Wohlfahrt, was focused on translational outcomes. © HZDR/Rainer Weisflog

Pressenotiz vom 1. Juli 2021 in Physics World

Together with its clinical partners in Europe and the US, Siemens Healthineers is focusing on translational research and technology innovation to drive continuous improvement in the planning, delivery and management of proton therapy for cancer patients

From collaboration comes innovation: that’s certainly the mantra of an ambitious, multicentre German R&D initiative which is leveraging the cross-disciplinary expertise of academic researchers, clinicians and industry to deliver game-changing advances in the radiation oncology clinic – enhancing the accuracy, safety and tissue-sparing capability of proton therapy systems in the process. The breakthroughs in question stem from the clinical deployment of dual-energy CT (DECT) for proton treatment planning and the application of so-called DirectSPR software1,2 for the more accurate prediction of proton range in the patient’s body. All part of a unifying vision – think translational research meets clinical application – to reimagine the planning, delivery and management of proton treatments tailored to the unique requirements of individual cancer patients.

Zum vollständigen Artikel geht es hier.